Safety
treatment-emergent adverse events, chemotherapy-induced peripheral neuropathy, adverse drug reactions
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, ADVERSE DRUG REACTIONS
The incidence of treatment-emergent adverse events (TEAEs) was 76.9% (40/52 patients), and the incidence of AEs related to the study drug (ADRs) was 30.8% (16/52 patients) (Table Incidences of adverse drug reactions in patients with chemotherapy-induced peripheral neuropathy in the MiroCIP interventional study (safety analysis set)


